Tumour heterogeneity and resistance to cancer therapies (original) (raw)

• Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
  Article CAS PubMed Google Scholar
• Jordan, E. J. et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 7, 596–609 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Blanke, C. D. et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26, 620–625 (2008).
  Article CAS PubMed Google Scholar
• Bhang, H. E. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440–448 (2015).
  Article CAS PubMed Google Scholar
• Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
  Article CAS PubMed Google Scholar
• Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 518, 240–244 (2015).
  Article CAS PubMed Google Scholar
• Kwak, E. L. et al. Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-amplified esophagogastric cancer. Cancer Discov. 5, 1271–1281 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Russo, M. et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 6, 147–153 (2016).
  Article CAS PubMed Google Scholar
• Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet. 38, 1043–1048 (2006).
  Article CAS PubMed Google Scholar
• Cleaver, J. E. & Crowley, E. UV damage, DNA repair and skin carcinogenesis. Front. Biosci. 7, d1024–d1043 (2002).
  CAS PubMed Google Scholar
• Roberts, S. A. & Gordenin, D. A. Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 14, 786–800 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, V. et al. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist 21, 1200–1211 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15–26 (2015).
  Article CAS PubMed Google Scholar
• Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121–1134 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Pleasance, E. D. et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463, 184–190 (2010).
  Article CAS PubMed Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).
• Murugaesu, N. et al. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy. Cancer Discov. 5, 821–831 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Findlay, J. M. et al. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy. Nat. Commun. 7, 11111 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Loeb, L. A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075–3079 (1991).
  CAS PubMed Google Scholar
• Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability — an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220–228 (2010).
  Article CAS PubMed Google Scholar
• Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 45, 970–976 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Burns, M. B., Temiz, N. A. & Harris, R. S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 45, 977–983 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704–712 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet. 48, 1490–1499 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Kanu, N. et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol. 17, 185 (2016).
  Article PubMed PubMed Central Google Scholar
• Walker, B. A. et al. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun. 6, 6997 (2017).
  Article Google Scholar
• Sieuwerts, A. M. et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm. Cancer 5, 405–413 (2017).
  Article Google Scholar
• Holland, A. J. & Cleveland, D. W. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat. Rev. Mol. Cell Biol. 10, 478–487 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251–256 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109–1113 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Andor, N. et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat. Med. 22, 105–113 (2016).
  Article CAS PubMed Google Scholar
• Weaver, B. A., Silk, A. D., Montagna, C., Verdier-Pinard, P. & Cleveland, D. W. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 11, 25–36 (2007).
  Article CAS PubMed Google Scholar
• Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23–28 (1976).
  Article CAS PubMed Google Scholar
• Hiley, C., de Bruin, E. C., McGranahan, N. & Swanton, C. Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol. 15, 453 (2014).
  Article PubMed PubMed Central Google Scholar
• Baca, S. C. et al. Punctuated evolution of prostate cancer genomes. Cell 153, 666–677 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506–510 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Hong, M. K. et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 6, 6605 (2015).
  Article CAS PubMed Google Scholar
• Cleary, A. S., Leonard, T. L., Gestl, S. A. & Gunther, E. J. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature 508, 113–117 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353–357 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Maddipati, R. & Stanger, B. Z. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 5, 1086–1097 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751–759 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Hao, J. J. et al. Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma. Nat. Genet. 48, 1500–1507 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Harbst, K. et al. Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma. Cancer Res. 76, 4765–4774 (2016).
  Article CAS PubMed Google Scholar
• Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Sankin, A. et al. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med. 3, 1485–1492 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Navin, N. et al. Tumor evolution inferred by single cell sequencing. Nature 472, 90–94 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Xu, X. et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148, 886–895 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Francis, J. M. et al. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing. Cancer Discov. 4, 956–971 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, C. et al. Discovery of biclonal origin and a novel oncogene SLC12A5 in colon cancer by single-cell sequencing. Cell Res. 24, 701–712 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Piotrowska, Z. et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov. 5, 713–722 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Boutros, P. C. et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47, 736–745 (2015).
  Article CAS PubMed Google Scholar
• Cooper, C. S. et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat. Genet. 47, 367–372 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Izumchenko, E. et al. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat. Commun. 6, 8258 (2015).
  Article PubMed Google Scholar
• Shain, A. H. et al. The genetic evolution of melanoma from precursor lesions. N. Engl. J. Med. 373, 1926–1936 (2015).
  Article PubMed Google Scholar
• Martinez, P. et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nat. Commun. 7, 12158 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• McPherson, A. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758–767 (2016).
  Article CAS PubMed Google Scholar
• Kemper, K. et al. Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts. EMBO Mol. Med. 7, 1104–1118 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Almendro, V. et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 74, 1338–1348 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, M. Y. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315–1326 (2009).
  Article PubMed PubMed Central Google Scholar
• Naxerova, K. et al. Origins of lymphatic and distant metastases in human colorectal cancer. Science 357, 55–60 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5, 1164–1177 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480–1486 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Goyal, L. et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7, 252–263 (2017).
  Article CAS PubMed Google Scholar
• Niederst, M. J. et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat. Commun. 6, 6377 (2015).
  Article CAS PubMed Google Scholar
• Savas, P. et al. The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program “CASCADE”. PLoS Med. 13, e1002204 (2016).
  Article PubMed PubMed Central Google Scholar
• Awad, M. M. et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368, 2395–2401 (2013).
  Article CAS PubMed Google Scholar
• Kris, M. G. et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311, 1998–2006 (2014).
  Article PubMed PubMed Central Google Scholar
• Gainor, J. F. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6, 1118–1133 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl Med. 3, 75ra26 (2011).
  Article PubMed PubMed Central Google Scholar
• Yu, H. A. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240–2247 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Shaw, A. T. et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 374, 54–61 (2016).
  Article CAS PubMed Google Scholar
• Yu, H. A. et al. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann. Oncol. 25, 423–428 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Hata, A. et al. Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI. J. Thorac. Oncol. 10, 1553–1559 (2015).
  Article CAS PubMed Google Scholar
• Carreira, S. et al. Tumor clone dynamics in lethal prostate cancer. Sci. Transl Med. 6, 254ra125 (2014).
  Article PubMed PubMed Central Google Scholar
• Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560–562 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Shafee, N. et al. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 68, 3243–3250 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Li, X. et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100, 672–679 (2008).
  Article CAS PubMed Google Scholar
• Raha, D. et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res. 74, 3579–3590 (2014).
  Article CAS PubMed Google Scholar
• Blakely, C. M. et al. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 11, 98–110 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Haq, R. et al. Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF. Cancer Cell 23, 302–315 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bivona, T. G. & Doebele, R. C. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat. Med. 22, 472–478 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Hata, A. N. et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat. Med. 22, 262–269 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Oxnard, G. R. et al. Association Between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J. Clin. Oncol. 34, 3375–3382 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Chabon, J. J. et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat. Commun. 7, 11815 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Nagrath, S. et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450, 1235–1239 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• San Lucas, F. A. et al. Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann. Oncol. 27, 635–641 (2016).
  Article CAS PubMed Google Scholar
• Sundaresan, T. K. et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin. Cancer Res. 22, 1103–1110 (2016).
  Article CAS PubMed Google Scholar
• Murtaza, M. et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497, 108–112 (2013).
  Article CAS PubMed Google Scholar
• Karlovich, C. et al. Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). Clin. Cancer Res. 22, 2386–2395 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Paweletz, C. P. et al. Bias-corrected targeted next-generation sequencing for rapid, multiplexed detection of actionable alterations in cell-free DNA from advanced lung cancer patients. Clin. Cancer Res. 22, 915–922 (2016).
  Article CAS PubMed Google Scholar
• Thierry, A. R. et al. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann. Oncol. 28, 2149–2159 (2017).
  Article CAS PubMed Google Scholar
• Forshew, T. et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl Med. 4, 136ra168 (2012).
  Article Google Scholar
• Newman, A. M. et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat. Med. 20, 548–554 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature 545, 446–451 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532–536 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Diaz, L. A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537–540 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Thress, K. Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial [abstract]. J. Clin. Oncol. 35, 9018 (2017).
  Article Google Scholar
• Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795–801 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Van Emburgh, B. O. et al. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat. Commun. 7, 13665 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Siena, S. et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase 2 trial of panitumumab-based therapy in metastatic colorectal cancer. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdx504 (2017).
• Bai, H. et al. Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer. PLoS ONE 8, e54170 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Suda, K. et al. Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. Lung Cancer 91, 36–40 (2016).
  Article PubMed Google Scholar
• Peters, S. et al. Alectinib versus crizotinib in untreated alk-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).
  Article CAS PubMed Google Scholar
• Ramalingam, S. et al. LBA1_PR: osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. J. Thorac. Oncol. 11, S152 (2016).
  Article Google Scholar
• Niederst, M. J. et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin. Cancer Res. 21, 3924–3933 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Das Thakur, M. & Stuart, D. D. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res. 73, 6106–6110 (2013).
  Article CAS PubMed Google Scholar
• Abdel-Wahab, O. et al. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. Cancer Discov. 4, 538–545 (2014).
  Article PubMed PubMed Central Google Scholar
• Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl Med. 3, 90ra59 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Pirazzoli, V. et al. Afatinib plus cetuximab delays resistance compared to single-agent erlotinib or afatinib in mouse models of TKI-naive EGFR L858R-induced lung adenocarcinoma. Clin. Cancer Res. 22, 426–435 (2016).
  Article CAS PubMed Google Scholar
• Janjigian, Y. Y. et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 4, 1036–1045 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463, 501–506 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Tricker, E. M. et al. Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov. 5, 960–971 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Hrustanovic, G. et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med. 21, 1038–1047 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Turke, A. B. et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17, 77–88 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lee, J. K. et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J. Clin. Oncol. 35, 3065–3074 (2017).
  Article CAS PubMed Google Scholar
• Chaib, I. et al. Co-activation of STAT3 and YES-associated protein 1 (YAP1) pathway in EGFR-mutant NSCLC. J. Natl Cancer Inst. 109, djx014 (2017).
  Article PubMed PubMed Central Google Scholar
• Carson, R. et al. HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF-mutant colorectal cancer by downregulation of c-FLIPL. Clin. Cancer Res. 21, 3230–3240 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Gomez, D. R. et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 17, 1672–1682 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Johanns, T. M. et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 6, 1230–1236 (2016).
  Article PubMed PubMed Central Google Scholar
• Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Santin, A. D. et al. Regression of chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin. Cancer Res. 22, 5682–5687 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. FDA https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm560040.htm (2017).